Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer

  • Takeshi Suto
  • , Megumi Ishiguro
  • , Chikuma Hamada
  • , Katsuyuki Kunieda
  • , Hiroyuki Masuko
  • , Ken Kondo
  • , Hideyuki Ishida
  • , Genichi Nishimura
  • , Kazuaki Sasaki
  • , Takayuki Morita
  • , Shoichi Hazama
  • , Koutarou Maeda
  • , Hideyuki Mishima
  • , Hideyuki Ike
  • , Sotaro Sadahiro
  • , Kenichi Sugihara
  • , Masazumi Okajima
  • , Shigetoyo Saji
  • , Junichi Sakamoto
  • , Naohiro Tomita

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Medicine and Dentistry